PORTLAND, Oregon, November 15, 2016 /PRNewswire/ --
Global Renal Denervation Market projects the renal denervation market was worth $197 million in 2015 and is expected to reach $3,153 million by 2022 with a CAGR of 48.5%, according to new research published by Allied Market Research. Symplicity Renal Denervation System is estimated to continue generating highest revenue throughout the forecast period, owing to growing number of product approvals across the globe. Europe held the leading position in the global market in 2015, and is expected to maintain its lead in the future.
Increasing prevalence and incidence of hypertension and blood pressure, changing lifestyle of the people, improvement of healthcare infrastructure in developing countries, and cost effectiveness of the renal denervation procedure as compared to other multidrug treatment therapies propel the market growth. However, stringent approval process for renal denervation devices, and patient discomfort and pain that arises during the procedure hamper the market growth.
Summary of the Renal Denervation Market Report can be accessed on the website at: https://www.alliedmarketresearch.com/renal-denervation-devices-market
Vessix Renal Denervation System is projected to be the fastest growing segment, with a CAGR of 57.6% from 2016 to 2022, as this system can be used for arteries of variable diameter (has a balloon that can be expanded into variable sizes). In addition, it uses a full-color graphic user interface that increases the accuracy and operation of the device. Boston Scientific, manufacturer of Vessix Renal Denervation System, considers this market to be a potential growth opportunity for expanding its business. Symplicity is the major and most frequently used product of the renal denervation market. "According to the CIRSE Member Survey (2013), Symplicity is used by approximately 78% of the European hospitals. This system is generally preferred as it delivers low level of RF energy and thus reduces the potential risks associated with high levels of RF radiation on body tissues". Says Deepa Tatkare, Senior Analyst, Healthcare Research at AMR
Radiofrequency was the most frequently used technology in the renal denervation market. In addition, it was the major segment in 2015 and is expected to lead throughout the forecast period. Ultrasound is projected to grow at the highest CAGR of 56.4%, as it overcomes the limitations of radiofrequency devices.
Key findings of Renal Denervation Market:
- On the basis of product type, the Symplicity Renal Denervation System segment accounted for the largest share, while Vessix Renal Denervation System is projected to grow at the fastest rate.
- Radiofrequency segment dominated the overall renal denervation market.
- Utrasound is poised to grow at the highest CAGR of 56.4% during the analysis period.
- Europe was the leading geographic market in 2015, and it is projected to lead for the next few years.
- Asia-Pacific is projected to grow at the highest CAGR of 50.6%.
Europes high share is attributed to the early start of this technology in European countries. In addition, most of the devices in this market have received a CE mark approval and are available for sales in the European region. On the other hand, North America accounts for a small proportion as renal denervation systems have not been approved by the FDA and are available only for investigational purpose in the North American market. Asia-Pacific is expected to grow at the fastest rate during the analysis period, owing to presence of ample growth opportunities in terms of unmet medical needs for the treatment of hypertension, increase in awareness about the use of advanced technologies such as renal denervation systems, and high prevalence rate of resistant hypertension.
Key players have adopted product development as their key strategy to cater to the changing needs of the industry. Major players operating in this market include Ablative Solutions, Inc., Boston Scientific Corporation, Cardiosonic Ltd, Kona Medical, Inc., Medtronic plc, Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, St. Jude Medical, Inc., and Terumo Medical Corporation. As of 2015, Medtronic dominated the overall renal denervation market, followed by St. Jude Medical.
Summary of Similar Reports can be viewed at: https://www.alliedmarketresearch.com/life-sciences/medical-devices-market-report
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1 (800) 792-5285 (U.S. & Canada)
Fax: +1 (855) 550-5975
SOURCE Allied Market Research